MSD has signed an agreement with Variational AI to use its generative AI (genAI) platform Enki in the discovery of new small-molecule medicines. Vancouver, Canada-based Variational – which emerged in ...
MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year. The green ...
A version of the below article first appeared in David Corn’s newsletter, Our Land. The newsletter comes out twice a week (most of the time) and provides behind-the-scenes stories and articles about ...
"Only Malware in the Building" is a monthly segment crafted through a collaboration between N2K CyberWire and the Proofpoint DISCARDED podcast. Hosted by Selena Larson, this segment focuses on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback